10 completed, 3 terminated, 2 unknown, 1 not yet recruiting. 17 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 17 | Completed 10, Terminated 3, Unknown 2, Not yet recruiting 1, Recruiting 1 |
Follow Mabthera: new trials by email Literature Review of Mabthera trials Research Report on Mabthera
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis. Rituximab - ANCA Associated Vasculitis (AAV), Polyangiitis (GPA) | Phase 4 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 70 | 2026-02-01 | 2026-03-05 |
| Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis Rituximab - Rheumatoid Arthritis | Phase 4 | Recruiting | Universitaire Ziekenhuizen KU Leuven | 134 | 2024-01-09 | 2025-05-31 |
| IVIG/Rituximab vs Rituximab in Kidney Transplant With de Novo Donor-specific Antibodies Rituximab, intravenous immune globulin - Renal Transplant | Phase 4 | Completed | Seoul National University Hospital | 50 | 2019-01-08 | 2022-10-26 |
| The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia Bortezomib, Rituximab - Waldenström Macroglobulinemia | Phase 4 | Completed | Institute of Hematology & Blood Diseases Hospital, China | 35 | 2016-05-01 | 2026-02-11 |
| A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action Remicade, Orencia, Ro-Actemra - Rheumatoid Arthritis | Phase 4 | Completed | Medical University of Vienna | 115 | 2012-05-01 | 2018-10-31 |
| Rituximab in Recurrent IgA Nephropathy Intravenous Rituximab, ACEI/ARB and corticosteroids - Recurrent IgA Nephropathy | Phase 4 | Unknown | Chulalongkorn University | 30 | 2012-01-01 | 2015-10-08 |
| Rituximab (RTX) Therapy in Patients With Active TAO Rituximab, Iv Methylprednisolone, peroral methylprednisolone and Methotrexate - Ophthalmopathy, Thyroid-Associated | Phase 4 | Completed | Göteborg University | 38 | 2011-12-01 | 2025-03-26 |
| A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status Cyclophosphamide, Fludarabine, Rituximab - Lymphocytic Leukemia, Chronic | Phase 4 | Terminated | Hoffmann-La Roche | 89 | 2011-06-17 | 2018-03-20 |
| A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status Chlorambucil, Cyclophosphamide, Fludarabine - Lymphocytic Leukemia, Chronic | Phase 4 | Terminated | Hoffmann-La Roche | 26 | 2011-04-27 | 2019-03-14 |
| De Novo Everolimus-based Therapy for Renal Transplantation Using Rituximab Induction rituximab and everolimus, thymoglobulin and tacrolimus - Renal Insufficiency | Phase 4 | Terminated | National Taiwan University Hospital | 2 | 2011-04-01 | 2012-12-27 |
| RituxiMab INDuction in Renal Transplantation Rituximab, Tacrolimus, Mycophenylate mofetil - Function of Renal Transplant | Phase 4 | Unknown | Guy's and St Thomas' NHS Foundation Trust | 100 | 2010-11-01 | 2020-07-22 |
| Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis Rituximab - DMARD Resistant Rheumatoid Arthritis | Phase 4 | Completed | Mashhad University of Medical Sciences | 44 | 2010-07-01 | 2012-05-08 |
| Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy etanercept or adalimumab, Rituximab - Rheumatoid Arthritis | Phase 4 | Completed | University of Glasgow | 302 | 2010-04-01 | 2015-05-29 |
| The Study of Different Dose Rituximab in the Treatment of ITP Rituximab - Purpura, Thrombocytopenic, Idiopathic, Immune Thrombocytopenia | Phase 4 | Completed | Shandong University | 62 | 2010-01-01 | 2017-08-23 |
| A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapies. rituximab, Methotrexate, Corticosteroid or NSAID - Rheumatoid Arthritis | Phase 4 | Completed | Hoffmann-La Roche | 40 | 2007-06-01 | 2014-11-04 |
| Study of Rituximab to Treat Chronic Renal Transplant Rejection Rituximab, Control arm - Kidney Transplantation, Graft Rejection | Phase 4 | Completed | King's College London | 62 | 2007-01-01 | 2020-03-05 |
| Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma Rituximab Fludarabine Cyclophosphamide - Non Hodgkin Lymphoma | Phase 4 | Completed | Asociacion Espanola de Hematologia y Hemoterapia | 75 | 2004-09-01 | 2010-05-17 |
Arthritis, Rheumatoid (5) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Glomerulonephritis, IGA (1) · Granulomatosis with Polyangiitis (1) · Graves Ophthalmopathy (1) · Lymphoma, Non-Hodgkin (1) · Microscopic Polyangiitis (1) · Purpura (1) · Purpura, Thrombocytopenic, Idiopathic (1) · Renal Insufficiency (1) · Systemic Vasculitis (1) · Thrombocytopenia (1) · Waldenstrom Macroglobulinemia (1)
Hoffmann-La Roche (3) · Asociacion Espanola de Hematologia y Hemoterapia (1) · Assistance Publique - Hôpitaux de Paris (1) · Chulalongkorn University (1) · Guy's and St Thomas' NHS Foundation Trust (1) · Göteborg University (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · King's College London (1) · Mashhad University of Medical Sciences (1) · Medical University of Vienna (1) · National Taiwan University Hospital (1) · Seoul National University Hospital (1) · Shandong University (1) · Universitaire Ziekenhuizen KU Leuven (1) · University of Glasgow (1)
Russia (3) · United Kingdom (3) · China (2) · South Korea (2) · Austria (1) · Belgium (1) · Czechia (1) · France (1) · Iran (1) · Spain (1) · Sweden (1) · Switzerland (1) · Taiwan (1) · Thailand (1)
A. Paz Coll, MD (1) · A. Salar, MD (1) · Anthony Dorling, PhD FRCP (1) · C. Cabrera Silva, MD (1) · Daniel Aletaha, MD (1) · Duncan Porter, BM BCh (1) · E . Prieto Pareja, MD (1) · Helena Filipsson, Ass Prof (1)
PMID 20546023, PMID 21674758, PMID 21710166, PMID 23293082, PMID 27040278, PMID 27197690, PMID 27889300, PMID 32117242, PMID 34792562, PMID 35049070, PMID 37169835, PMID 38205507, PMID 39407334, PMID 8217798
2009 (2), 2025 (1)